{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:57Z","timestamp":1792713657381,"version":"4.5.0"},"reference-count":77,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamapsychiatry.2019.1530","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T19:30:41Z","timestamp":1559590241000},"page":"1063","source":"Crossref","is-referenced-by-count":73,"title":["Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders"],"prefix":"10.1001","volume":"76","author":[{"given":"Stephanie","family":"Winkelbeiner","sequence":"first","affiliation":[{"name":"Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York"},{"name":"Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, New York"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York"},{"name":"University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[{"name":"Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York"},{"name":"Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, New York"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Homan","sequence":"additional","affiliation":[{"name":"Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York"},{"name":"Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, New York"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"yoi190038r1","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4088\/JCP.v61n1213","article-title":"Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.","volume":"61","author":"Garver","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"yoi190038r2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/sim.6739","article-title":"Mastering variation: variance components and personalised medicine.","volume":"35","author":"Senn","year":"2016","journal-title":"Stat Med"},{"issue":"7","key":"yoi190038r3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Trying to be precise about vagueness.","volume":"26","author":"Senn","year":"2007","journal-title":"Stat Med"},{"issue":"4","key":"yoi190038r4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/acps.2018.138.issue-4","article-title":"Clozapine as an early-stage treatment.","volume":"138","author":"Homan","year":"2018","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"yoi190038r5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1152\/japplphysiol.00714.2014","article-title":"Individual response to exercise training - a statistical perspective.","volume":"118","author":"Hecksteden","year":"2015","journal-title":"J Appl Physiol (1985)"},{"issue":"6","key":"yoi190038r6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1152\/japplphysiol.00896.2017","article-title":"Repeated testing for the assessment of individual response to exercise training.","volume":"124","author":"Hecksteden","year":"2018","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"yoi190038r7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pain.2013.09.019","article-title":"Interpreting patient treatment response in analgesic clinical trials: implications for genotyping, phenotyping, and personalized pain treatment.","volume":"155","author":"Dworkin","year":"2014","journal-title":"Pain"},{"key":"yoi190038r9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12688\/f1000research","article-title":"Does evidence support the high expectations placed in precision medicine? A bibliographic review.","volume":"7","author":"Cort\u00e9s","year":"2019","journal-title":"F1000 Res"},{"issue":"2","key":"yoi190038r10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/2041-210X.12309","article-title":"Meta-analysis of variation: ecological and evolutionary applications and beyond.","volume":"6","author":"Nakagawa","year":"2015","journal-title":"Methods Ecol Evol"},{"issue":"3","key":"yoi190038r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"11","key":"yoi190038r12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamapsychiatry.2017.2663","article-title":"Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis.","volume":"74","author":"Brugger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"yoi190038r13","article-title":"A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis","author":"Pillinger","year":"2018","journal-title":"Schizophr Bull"},{"issue":"10","key":"yoi190038r14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi190038r15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1192\/bjp.bp.117.201103","article-title":"Do antipsychotic drugs lose their efficacy for relapse prevention over time?","volume":"211","author":"Leucht","year":"2017","journal-title":"Br J Psychiatry"},{"issue":"5220","key":"yoi190038r16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1126\/science.7604277","article-title":"Sex differences in mental test scores, variability, and numbers of high-scoring individuals.","volume":"269","author":"Hedges","year":"1995","journal-title":"Science"},{"issue":"1-3","key":"yoi190038r17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study.","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr Res"},{"issue":"5","key":"yoi190038r19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial.","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"yoi190038r20","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.","volume":"28","author":"Potkin","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"37","key":"yoi190038r21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/0006-3223(95)94656-H","article-title":"Efficacy and safety of sertindole in a trial of schizophrenic patients.","volume":"9","author":"Zborowski","year":"1995","journal-title":"Biol Psychiatry"},{"issue":"6","key":"yoi190038r22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"1-3","key":"yoi190038r23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"issue":"12","key":"yoi190038r24","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"2-3","key":"yoi190038r25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res"},{"issue":"3","key":"yoi190038r26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","article-title":"Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"yoi190038r27","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"yoi190038r28","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"yoi190038r29","first-page":"2077","article-title":"A double-blind, placebo-controlled, comparative study of paliperidone extended release (ER) tablets in patients with schizophrenia.","volume":"13","author":"Hirayasu","year":"2010","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"3","key":"yoi190038r31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"yoi190038r32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia.","volume":"41","author":"McEvoy","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"1","key":"yoi190038r33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","article-title":"Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.","volume":"16","author":"Tzimos","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"yoi190038r35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"1-3","key":"yoi190038r36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","article-title":"Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies.","volume":"174","author":"Correll","year":"2016","journal-title":"Schizophr Res"},{"issue":"5","key":"yoi190038r37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/JCP.0b013e3181eeb600","article-title":"Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and\/or mood stabilizers.","volume":"30","author":"Canuso","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"yoi190038r38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.","volume":"53","author":"Shen","year":"2014","journal-title":"J Psychiatr Res"},{"issue":"2","key":"yoi190038r39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.","volume":"30","author":"Kane","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"yoi190038r41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: A 4-week randomized, double-blind, controlled trial.","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"7","key":"yoi190038r42","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia: results from the CandleLyte study.","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1-2","key":"yoi190038r43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF02245618","article-title":"A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.","volume":"124","author":"van Kammen","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"yoi190038r45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"yoi190038r46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/JCP.0000000000000071","article-title":"The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.","volume":"34","author":"Litman","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"yoi190038r47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"yoi190038r48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi190038r49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/hup.v28.2","article-title":"Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia.","volume":"28","author":"Egan","year":"2013","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"yoi190038r50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.","volume":"31","author":"Durgam","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"yoi190038r53","first-page":"957","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry.","volume":"168","author":"Meltzer","year":"2011"},{"issue":"2","key":"yoi190038r54","first-page":"446","article-title":"A randomized, doubleblind, placebo-controlled efficacy and safety study of bifeprunox as treatment for patients with acutely exacerbated schizophrenia.","volume":"33","author":"Meltzer","year":"2007","journal-title":"Schizophr Bull"},{"issue":"1-3","key":"yoi190038r55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"issue":"4","key":"yoi190038r56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial.","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"yoi190038r57","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"issue":"1-3","key":"yoi190038r58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"issue":"5","key":"yoi190038r59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","article-title":"A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.","volume":"71","author":"Canuso","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"yoi190038r61","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"1-2","key":"yoi190038r63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.","volume":"124","author":"Beasley","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"yoi190038r64","first-page":"11","article-title":"The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.","volume":"41","author":"Lindenmayer","year":"2008","journal-title":"Psychopharmacol Bull"},{"issue":"10","key":"yoi190038r65","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.euroneuro.2012.02.007","article-title":"A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia.","volume":"22","author":"Schmidt","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"yoi190038r66","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi190038r67","first-page":"54","article-title":"Efficacy and safety of paliperidone extended release 1.5 mg\/day-a double-blind, placebo- and active-controlled, study in the treatment of patients with schizophrenia.","volume":"44","author":"Coppola","year":"2011","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"yoi190038r68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"yoi190038r69","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/sim.5713","article-title":"Seven myths of randomisation in clinical trials.","volume":"32","author":"Senn","year":"2013","journal-title":"Stat Med"},{"issue":"4","key":"yoi190038r70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamapsychiatry.2017.4704","article-title":"Enthusiasm and skepticism about using national registers to analyze psychotropic drug outcomes.","volume":"75","author":"Leucht","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yoi190038r71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/acps.12960","article-title":"Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.","volume":"139","author":"Kubo","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"21","key":"yoi190038r72","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","article-title":"Is the placebo powerless? an analysis of clinical trials comparing placebo with no treatment.","volume":"344","author":"Hr\u00f3bjartsson","year":"2001","journal-title":"N Engl J Med"},{"issue":"7157","key":"yoi190038r73","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/bmj.317.7157.537","article-title":"Applying results of randomised trials to patients. N of 1 trials are needed.","volume":"317","author":"Senn","year":"1998","journal-title":"BMJ"},{"issue":"21","key":"yoi190038r74","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine\u2013reporting of subgroup analyses in clinical trials.","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"yoi190038r75","doi-asserted-by":"publisher","first-page":"e0167167","DOI":"10.1371\/journal.pone.0167167","article-title":"Understanding variation in sets of N-of-1 trials.","volume":"11","author":"Araujo","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"yoi190038r76","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0033291717001726","article-title":"Are we failing clinical trials? a case for strong aggregate outcomes.","volume":"48","author":"Joyce","year":"2018","journal-title":"Psychol Med"},{"issue":"2","key":"yoi190038r77","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1214\/07-AOAS124","article-title":"Interpretation of interaction: a review.","volume":"1","author":"Gonz\u00e1lez","year":"2007","journal-title":"Ann Appl Stat"},{"key":"yoi190038r8","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198555520.001.0001","volume-title":"Statistical Inference and Analysis: Selected Correspondence of RA Fisher","author":"Bennett","year":"1990"},{"key":"yoi190038r18","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"StudyRIS","year":"1996"},{"key":"yoi190038r30","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"Leucht","year":"2009"},{"key":"yoi190038r40","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"Cited by: Leucht","year":"2002"},{"key":"yoi190038r44","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"Leucht","year":"2002"},{"key":"yoi190038r51"},{"key":"yoi190038r52","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"Leucht","year":"2010"},{"key":"yoi190038r60","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"Leucht","year":"2009"},{"key":"yoi190038r62","first-page":"927","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors.","volume-title":"Am J Psychiatry","author":"Leucht","year":"2000"},{"key":"yoi190038r34","unstructured":"ClinicalTrials.gov. A study of the efficacy and safety of asenapine in participants with an acute exacerbation of schizophrenia. Identifier: NCT01617187. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01617187?cond=A+study+of+the+efficacy+and+safety+of+asenapine+in+participants+with+an+acute+exacerbation+of+schizophrenia&rank=1. Accessed October 31, 2016."}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2735440\/jamapsychiatry_winkelbeiner_2019_oi_190038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:37:37Z","timestamp":1721342257000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2735440"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1530","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}